Assenagon Asset Management S.A. Sells 47,897 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Assenagon Asset Management S.A. cut its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 31.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 102,691 shares of the specialty pharmaceutical company’s stock after selling 47,897 shares during the period. Assenagon Asset Management S.A. owned about 0.32% of Collegium Pharmaceutical worth $3,065,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of COLL. New Age Alpha Advisors LLC purchased a new stake in Collegium Pharmaceutical in the 4th quarter worth about $40,000. Virtus Fund Advisers LLC boosted its stake in shares of Collegium Pharmaceutical by 30.5% during the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 565 shares in the last quarter. FORA Capital LLC bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at about $223,000. Aigen Investment Management LP purchased a new position in Collegium Pharmaceutical during the 4th quarter valued at about $230,000. Finally, Summit Global Investments purchased a new position in Collegium Pharmaceutical in the fourth quarter worth about $232,000.

Insider Activity

In other Collegium Pharmaceutical news, Director John Gordon Freund sold 6,601 shares of the firm’s stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $30.62, for a total value of $202,122.62. Following the sale, the director now directly owns 70,658 shares of the company’s stock, valued at approximately $2,163,547.96. This trade represents a 8.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 2.51% of the company’s stock.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $29.71 on Tuesday. The firm has a market cap of $954.64 million, a PE ratio of 12.81 and a beta of 0.63. The firm has a fifty day moving average of $28.27 and a 200 day moving average of $29.55. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. Collegium Pharmaceutical, Inc. has a one year low of $23.23 and a one year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 EPS for the quarter, missing analysts’ consensus estimates of $1.50 by ($0.01). The company had revenue of $177.76 million during the quarter, compared to analyst estimates of $174.96 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company’s quarterly revenue was up 22.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.45 EPS. As a group, research analysts predict that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 19th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Needham & Company LLC reaffirmed a “buy” rating and issued a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Finally, Piper Sandler reiterated a “neutral” rating and set a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Moderate Buy” and an average price target of $43.75.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.